NCT05786040View on ClinicalTrials.gov

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 23, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Monomorphic B-Cell Post-Transplant Lymphoproliferative DisorderPolymorphic Post-Transplant Lymphoproliferative Disorder
Interventions
PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Positron Emission Tomography

Undergo PET

BIOLOGICAL

Rituximab

Given IV or SC

BIOLOGICAL

Tafasitamab

Given IV

Trial Locations (3)

27278

RECRUITING

University of North Carolina-Hillsborough Campus, Hillsborough

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

08903

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

Timothy Voorhees

OTHER